抗癌方联合吉非替尼治疗晚期NSCLC患者癌因性疲乏的疗效及对生活质量的影响  

Efficacy of Anticancer Regimen Combined with Gefitinib in the Treatment of Cancer-related Fatigue in Advanced Non-small Cell Lung Cancer Patient

作　　者：黄凤灵 李健哲[2] HUANG Feng-lin;LI Jian-zhe(Tianyang County Chinese Medicine Hospital 533600)

机构地区：[1]广西中医药大学附属瑞康医院田阳院区药剂科(田阳县中医医院),广西百色533600 [2]广西中医药大学附属瑞康医院药学部,广西南宁530011

出　　处：《医学临床研究》2019年第5期833-835,838,共4页Journal of Clinical Research

基　　金：国家自然科学基金(编号:81460613).

摘　　要：【目的】探讨抗癌方联合吉非替尼治疗癌因性疲乏的疗效及对患者生活质量的影响。【方法】123例晚期非小细胞肺癌(NSCLC)患者,根据治疗方法不同将患者分为两组,对照组采用吉非替尼治疗,观察组在对照组基础上联合抗癌方治疗。比较两组患者治疗后疗效、治疗前后生活质量评分、PFS评分等情况。【结果】两组患者PFS评分均低于治疗前(P<0.05),观察组下降程度高于对照组(P<0.05)。治疗后两组患者倦怠乏力、肋疼、五心烦热及脉虚无力评分均低于治疗前(P<0.05),且观察组明显低于对照组(P<0.05)。观察组治疗后总缓解率为69.68%,明显高于对照组的40.98%(P<0.05)。治疗后两组患者躯体功能、角色功能、情绪功能评分均高于治疗前(P<0.05),且观察组上述评分升高幅度高于对照组(P<0.05)。回归分析显示年龄、病理分级与晚期NSCLC患者生活质量呈负相关,心理干预、治疗方式与患者生活质量呈正相关。【结论】抗癌方联合吉非替尼治疗晚期NSCLC患者癌因性疲乏的疗效较好,能明显改善患者生活质量。【Objective】To investigate the efficacy of anticancer regimen combined with gefitinib in the treatment of cancer-related fatigue and its impact on quality of life.【Methods】A total of 123 patients with advanced non-small cell lung cancer (NSCLC) were divided into two groups according to the treatment methods. Patients in the control group(group B)received gefitinib, while patients in the observation group(group A) received gefitinib combined with anti-cancer treatment. The therapeutic effects, quality of life scores and the PFS score in the two groups before and after treatment were compared.【Results】The PFS scores of the two groups were lower than those before treatment (P<0.05), and the decrease in group A was higher than that in group B (P<0.05). After treatment, the fatigue, rib pain, five upset fever and pulse weakness scores of the two groups were lower than before treatment (P<0.05).Those scores in group A were significantly lower than group B (P<0.05). The total remission rate of group A was 69.68%, which was significantly higher than group B (40.98%)(P<0.05). After treatment, the scores of physical function, role function and emotional function in the two groups were higher than those before treatment (P<0.05). The increase in the above scores in group A was higher than group B (P<0.05). Regression analysis showed that age and pathological grade were negatively correlated with quality of life in patients with advanced NSCLC. However, psychological intervention and treatment were positively correlated with quality of life in those patients.【Conclusion】Anticancer combined with gefitinib is effective in treating cancer-related fatigue in patients with advanced NSCLC , and can significantly improve the quality of life of patients.

关 键 词：癌 非小细胞肺/药物疗法 喹唑啉类/治疗应用 

分 类 号：R734.2[医药卫生—肿瘤]